




1634
JFW

Patent Application
Attorney Docket No.PC11028A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 19th day of July, 2004.

By _____


(Signature of person mailing)

Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: L. Kathryn Durham, et al. :

APPLICATION NO.: 10/032,241 : Examiner: S. A. Sakelaris

FILING DATE: 12/21/01 : Group Art Unit: 1634

TITLE: Methods, Compositions and Kits Relating to
Cardiovascular Disease

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Pursuant to the duty of disclosure set forth in 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. § 1.97 and § 1.98, Applicant(s) hereby bring to the Examiner's attention the enclosed PTO-FB-A820 and the listed documents, copies of which are also enclosed.

I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement. No fee is believed to be due, however, the Commissioner is authorized to charge any fees, which may be required, or credit any overpayment, to Account No. 16-1445.

The Examiner is requested to consider the cited documents and to indicate such consideration by returning a signed and initialed copy of the PTO-FB-A820 Form with the next communication from the Patent Office. Further, it is requested that the cited documents be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).




Patent Application
Attorney Docket No.PC11028A

Should there be any questions regarding the above or the present application, the Examiner is invited to contact the undersigned at the below-listed number.

Date: July 19, 2004

Respectfully submitted,


Gabriel L. Kleiman
Attorney for Applicant(s)
Reg. No. 40,681

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0041



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY. DOCKET NO. PC11028A

SERIAL NO. 10/032,241

APPLICANT L. Kathryn Durham et al.

FILING DATE 12/21/01

GROUP 1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Genbank abstract accession no. AL445584, 6 December 2000, Plumb, "Homo sapiens chromosome 9 clone RP11-366N18".
			Genbank abstract accession no. AC018492, 24 November 2000, Wang et al., "Homo sapiens chromosome 3 clone RP11-135E16 map 3p, complete sequence".
			Genbank abstract accession no. AE002611, 6 October 2000, Adams et al., "Drosophila melanogaster genomic scaffold 142000013385548, complete sequence".
			EMBL abstract accession no. HSCETP6, 26 November 1990, Agellon et al., "Human cholestry ester transfer protein (CETP) gene, exons 12-14".
			Genbank abstract accession no. AC084456, 4 November 2000, Washington University Genome Sequencing Center, "Caenorhabditis briggsae cosmid CB029P18, complete sequence".
			Gene, Vol. 197, 1997, Williams et al., "Sequencing of the cholestry ester transfer protein 5' regulatory region using artificial transposons", pages 101-107.
			Clinical Genetics, Vol. 51, 1997, Ramsbottom et al., "The cholestry ester transfer protein (CETP) locus as a candidate gene in abdominal aortic aneurysm", pages 241-245.
			Genetic Epidemiology, Vol. 19, 2000, Corbex et al., "Extensive Association Analysis Between the CETP Gene and Coronary Heart Disease Phenotypes Reveals Several Putative Functional Polymorphisms and Gene-Environmental Interactions", pages 64-80.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.